Abstract
Fourteen patients with acute myelogenous leukaemia, who had either failed to enter remission or had relapsed following conventional chemotherapy, received human lymphoblastoid interferon (Hu IFN-alpha N) at a dose of 100 X 10(6) units/m2 daily by continuous IV infusion for 7 days. Complete remission was not achieved in any of 10 patients evaluable for response, although a transient decrease in the degree of bone marrow infiltration was observed in two patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
